PsyTech

Dedicated to driving psychedelic research, education, and innovation forward. 

OUR MISSION

PsyTech is building a vibrant community designed to explore psychedelic health and wellness, combat stigma, and accelerate innovation. Empowered by the advancement of groundbreaking clinical research, we foster and steer innovation in psychedelics to serve the greater good.

WHY US?

PsyTech was incubated by iCAN (Israel-Cannabis) and developed by the team behind CannaTech, the premiere international cannabis summit. Leveraging the highly relevant experience of iCAN, PsyTech is positioned to lead the global psychedelics conversation forward.

WHY NOW?

In 1971, psychedelics were classified as a Schedule I drug in the United States, shutting down all the promising research that had been conducted since the late 1940s. Recently, psychedelics have re-emerged and are experiencing a radical renaissance as their potential to treat a wide variety of health conditions is being recognized. Today, patients, physicians, and research scientists are expressing an urgency in accelerating psychedelic medicine to its full potential. It is this urgency that inspired the creation of PsyTech.

HOW DO WE DRIVE INNOVATION?

We drive psychedelics forward by building community in a wide range of sectors, including clinical research/biochemistry, patient advocacy, regulatory and public policy, and investment and business development as we advance ventures in this burgeoning industry. 

In service to our mission, PsyTech operates two branches:

CONNECT

Our live global summits, virtual events, and online community resources are designed to build a psychedelic movement and push good research, compassionate public policy, and responsible business forward.

DISCOVERY

Leveraging the PsyTech community, we directly advance promising ventures in psychedelics.

 

Stay updated

Sign up for our newsletter and tell us about your interest in psychedelic medicines.